The overall goal of the laboratory of John A. Copland, Ph.D., at Mayo Clinic in Florida is to understand molecular mechanisms of carcinogenesis and tumor progression.
Toward that goal, the laboratory:
- Is genomically profiling human carcinomas to identify aberrant signaling pathways, then further exploring these pathways in order to create novel, synergistic cancer therapies
- Has identified RhoB as a key modulator for drug response in anaplastic thyroid carcinoma for inhibiting growth and inducing cell death
- Has discovered that type III TGFbeta receptor and GATA3 signaling play important roles in tumor progression and metastasis in renal cell carcinoma
- Is interested in creating valid preclinical models, which mimic the tumor of a patient, to develop a better understanding of how a tumor originates, survives and metastasizes